The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis [PDF]
, 2003 Patients in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomized to receive 400 mg moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days. Sixteen-hour overnight sputa collections were made for the
Bongard, E +7 more
core +1 more source
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. [PDF]
, 2020 BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia.
Abass, KM +31 more
core +3 more sources
Rifampin-resistant Meningococcal Disease
Emerging Infectious Diseases, 2005 Rifampin-resistant meningococcal disease occurred in a child who had completed rifampin chemoprophylaxis for exposure to a sibling with meningococcemia. Susceptibility testing of 331 case isolates found only 1 other case of rifampin-resistant disease in ...
Jean Rainbow +5 more
doaj +1 more source
Rifampin (INN Rifampicin) [PDF]
Journal of Pain and Symptom Management, 2015 Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available on www.palliativedrugs.com. Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and
Mary Mihalyo +5 more
openaire +2 more sources
In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant acinetobacter baumannii [PDF]
, 2019 Carbapenem-resistant Acinetobacter baumannii (CR-Ab) infections are associated with high morbidity and mortality. The aim of the study was to evaluate the in-vitro activity of different antimicrobial combinations (with and without colistin, COL) against ...
De Angelis, Massimiliano +6 more
core +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Frontiers in Pharmacology, 2016 Membrane drug transporters contribute to the disposition of many drugs. In human liver, drug transport is controlled by two main superfamilies of transporters, the solute carrier transporters (SLC) and the ATP Binding Cassette transporters (ABC). Altered
Eric A Benson +8 more
doaj +1 more source
Genome-Wide Transposon Screen of a Pseudomonas syringae mexB Mutant Reveals the Substrates of Efflux Transporters. [PDF]
, 2019 Bacteria express numerous efflux transporters that confer resistance to diverse toxicants present in their environment. Due to a high level of functional redundancy of these transporters, it is difficult to identify those that are of most importance in ...
Deutschbauer, Adam M +4 more
core +1 more source
A literature review of liver function test elevations in rifampin drug–drug interaction studies
Clinical and Translational Science, 2022 Although rifampin drug–drug interaction (DDI) studies are routinely conducted, there have been instances of liver function test (LFT) elevations, warranting further evaluation.
Sherry M. Ibrahim +3 more
doaj +1 more source
Susceptibility of Mycobacteria to Rifampin [PDF]
Antimicrobial Agents and Chemotherapy, 1972 The Mycobacterium species M. tuberculosis, M. avium-intracellulare, M. kansasii, M. marinum, M. scrofulaceum, M. fortuitum, M. terrae , and M. gordonae were analyzed for their susceptibility to rifampin. M. tuberculosis, M. kansasii , and
Hugo L. David +3 more
openaire +3 more sources